Neurocrine Biosciences NBIX · NASDAQ
$135.71 -0.91% (-$1.24)
Summary
88 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 44% a year over the last 3 years.
- Out of every 100 USD of revenue, 21 USD is left as net profit.
- Analysts expect revenue to grow by 36% this fiscal year.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 19.7 USD for 1 USD of yearly profit. Over the last five years it was 58.9 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 24% a year. For the next fiscal year analysts expect revenue to grow by 36%. Earnings per share grew by 44% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 2.0 USD
- Research and development 34 USD
- Sales and administration 41 USD
- Taxes and other 2.5 USD
- Net profit 21 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 21 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 32
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $204.18 is 50% above today's price. 86% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 99%
- Collaboration Revenue 0.9%
By region
The company reports no revenue by region.
Product brings in 99% of revenue.
Segments in detail